Zevra Therapeutics Inc (NASDAQ: ZVRA) stock closed at $6.49 on 7/31/24 after a major increase of 18.0%. Moreover, this advance was accompanied by exceptionally high trading volume at 1002% of normal. The stock has risen 3.5% during the last week but has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
ZVRA is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Zevra Therapeutics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Zevra Therapeutics has a poor Power Rating of 21 and a very low Appreciation Score of 2, and the Lowest Value Trend Rating results.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment